Proscia and Visiopharm have joined forces to deliver a unified solution that combines Visiopharm’s suite of CE-IVD clinical AI applications – including breast IHC markers, breast metastasis detection, and colon metastasis detection – with Proscia’s CE-IVD Concentriq Dx platform for image-based data and workflow management.
Featured Story:
Latest Articles
March 5, 2024
February 27, 2024